If GEP100 also interacts with HGFR besides EGFR, about 40–80% of breast cancers may utilize the GEP100-Arf6-AMAP1 pathway, although this might not be the sole pathway for their invasion and malignancy. Here, ARF6 is linked to breast carcinoma.